Alprostadil: Risks & Legal Status

Critical Safety Information#

Alprostadil (prostaglandin E1) is an FDA-approved prescription medication with well-characterized risks based on extensive clinical trial data and decades of post-marketing surveillance. Unlike many investigational compounds, alprostadil's risk profile is supported by rigorous regulatory review and large patient databases. This page summarizes the most important risks, warnings, and regulatory information for patients and clinicians.

Primary Clinical Risks#

Priapism -- Urological Emergency#

Priapism is the most serious acute risk associated with alprostadil use for erectile dysfunction. It is defined as a persistent erection lasting more than 4 hours without sexual stimulation and represents a urological emergency.

Pathophysiology: Alprostadil-induced priapism is of the ischemic (low-flow, veno-occlusive) type. Prolonged smooth muscle relaxation in the corpora cavernosa prevents venous outflow, leading to blood stasis, progressive deoxygenation, acidosis, and eventual ischemic injury to the corporal smooth muscle. If untreated beyond 4-6 hours, irreversible smooth muscle necrosis begins, which can result in permanent erectile dysfunction.

Incidence: In clinical trials, priapism occurred in approximately 1-4% of patients using intracavernosal alprostadil. The risk is dose-dependent and is highest during the initial dose-titration phase, which is why mandatory in-office titration is required. With MUSE (intraurethral), priapism occurs in fewer than 1% of patients.

Risk factors for priapism:

• Dose exceeding the patient's optimal titrated dose
• Conditions affecting blood rheology: sickle cell disease or trait, thalassemia, polycythemia vera, thrombocythemia
• Hematological malignancies: leukemia, multiple myeloma (corporal infiltration)
• Concurrent use of other vasoactive agents (PDE5 inhibitors, papaverine, phentolamine)
• Neurogenic erectile dysfunction (may be more sensitive to lower doses)
• Impaired hepatic metabolism (reduced clearance of alprostadil metabolites)

Emergency management protocol:

1. If erection lasts more than 4 hours, seek immediate emergency medical care
2. The physician should aspirate dark blood from the corpus cavernosum using a 19-gauge butterfly needle
3. If aspiration alone is insufficient, inject a sympathomimetic agent: phenylephrine (diluted to 100-500 mcg/mL) in 1 mL aliquots every 5-10 minutes (maximum dose 1 mg within 1 hour)
4. Phenylephrine is preferred over epinephrine due to lower risk of cardiac arrhythmia
5. Monitor blood pressure and heart rate during sympathomimetic administration
6. If pharmacological detumescence fails after 1 hour, surgical shunting procedures (distal or proximal cavernosal-spongiosal shunt) are indicated

Prevention:

• Strict adherence to the in-office dose titration protocol
• Use the lowest effective dose at all times
• Never exceed the maximum recommended dose (40-60 mcg per injection)
• Limit injection frequency to 3 times per week maximum
• Patients with any predisposing condition should not use alprostadil for ED
• Educate all patients about the signs and timing of priapism and the urgency of treatment

Penile Fibrosis and Peyronie-like Disease#

Repeated intracavernosal injections can lead to the development of fibrous tissue at injection sites, manifesting as palpable nodules, plaques, or penile curvature similar to Peyronie disease.

Incidence: Reported in approximately 2-12% of patients in clinical trials and long-term follow-up studies, with higher rates in patients injecting more frequently or using higher doses.

Pathophysiology: The fibrosis likely results from a combination of:

• Repeated mechanical trauma from needle insertion
• Local inflammatory response to the drug and vehicle
• Prostaglandin-mediated fibroblast activation at the injection site
• Extravasation of blood into the tunica albuginea from needle tracks

Clinical consequences:

• Palpable plaques or nodules that may interfere with injection
• Penile curvature that can affect sexual function
• Progressive difficulty achieving erections with injection therapy
• In severe cases, surgical intervention may be required

Monitoring and prevention:

• Regular self-examination by the patient for nodules or changes in penile shape
• Physician examination at follow-up visits (recommended every 3-6 months)
• Strict rotation of injection sites within the dorsolateral corpora cavernosa
• Limiting injection frequency to a maximum of 3 times per week
• Using the finest gauge needle practical (27-30 gauge)
• Discontinuation of injection therapy if significant fibrosis or curvature develops
• Alternative treatment (PDE5 inhibitors, vacuum devices, implant surgery) should be considered

Neonatal Apnea and Respiratory Depression#

In the neonatal critical care setting, apnea is the most significant risk of IV alprostadil infusion.

Incidence: Approximately 10-12% of neonates receiving IV alprostadil for PDA maintenance develop clinically significant apnea. The incidence is higher (approximately 20%) in neonates weighing less than 2 kg at birth.

Mechanism: PGE1 acts on central respiratory neurons in the brainstem to depress respiratory drive. This effect appears to be dose-related and is more pronounced in premature and low-birth-weight infants whose respiratory control mechanisms are already immature.

Clinical implications:

• Approximately 12% of neonates receiving alprostadil require endotracheal intubation and mechanical ventilation
• Apnea typically occurs within the first hour of infusion initiation
• The risk may decrease with dose reduction but does not completely disappear at lower maintenance doses
• Despite this risk, alprostadil remains life-saving for neonates with ductal-dependent congenital heart defects, as the alternative (ductal closure without surgical correction) carries a much higher mortality rate

Required safeguards:

• Administration exclusively in a neonatal intensive care unit
• Continuous cardiorespiratory monitoring (heart rate, respiratory rate, oxygen saturation)
• Intubation equipment and trained personnel immediately available at the bedside
• Use the lowest effective infusion rate (begin at 0.05 mcg/kg/min and titrate down to 0.01-0.02 mcg/kg/min once ductal patency is confirmed)
• Immediate notification of the medical team if apnea, bradycardia, or desaturation occurs

Additional Neonatal Risks with Prolonged Infusion#

When IV alprostadil is administered for extended periods (typically more than 120 hours), additional risks emerge:

Cortical proliferation of long bones (periosteal hyperostosis):

• Occurs in approximately 6-12% of neonates receiving prolonged infusion
• Manifests as periosteal new bone formation visible on radiographs, typically affecting the long bones
• Believed to be mediated by PGE1 stimulation of osteoblastic activity
• Generally reversible upon discontinuation of the infusion
• Monitored with periodic radiographs in neonates requiring prolonged therapy

Gastric outlet obstruction:

• Reported in approximately 1-7% of neonates receiving alprostadil for more than 2 weeks
• Results from antral mucosal hyperplasia and edema caused by local prostaglandin effects
• May manifest as feeding intolerance, vomiting, or gastric distension
• Typically resolves after discontinuation but may require temporary gastric decompression

Other reported effects:

• Fever (14%) -- prostaglandin-mediated effects on the hypothalamic thermostat
• Seizures (4%) -- difficult to attribute directly to alprostadil versus underlying cardiac pathology and hypoxia
• Flushing (10%) -- cutaneous vasodilation
• Hypotension (4%) -- systemic vasodilation requiring dose adjustment or vasopressor support
• Disseminated intravascular coagulation -- rare, related to antiplatelet effects in the setting of neonatal coagulopathy

Systemic Hypotension#

Alprostadil is a potent vasodilator, and systemic hypotension is a predictable pharmacological consequence, particularly with intravenous administration.

Clinical contexts where hypotension risk is greatest:

• IV infusion in neonates (especially premature or hemodynamically unstable)
• IV infusion for critical limb ischemia in elderly patients with cardiovascular comorbidities
• MUSE intraurethral use (greater systemic absorption than intracavernosal injection)
• Concurrent administration of antihypertensive medications
• First-dose administration in any route

Management:

• Blood pressure monitoring during initial dosing and during IV infusions
• Slow dose titration
• Patient should be supine or seated during administration
• Reduction or cessation of concurrent antihypertensive medications if clinically appropriate
• Volume resuscitation and vasopressors for severe hypotension

Regulatory and Legal Status#

Alprostadil is a fully regulated prescription pharmaceutical in all major jurisdictions. It is not a controlled substance and is not banned by WADA or sports governing bodies. Its regulatory status is fundamentally different from unregulated research compounds or investigational peptides.

United States (FDA)#

Alprostadil has received FDA approval for multiple indications across distinct formulations:

• Caverject (alprostadil for injection): Approved 1995 for treatment of erectile dysfunction due to neurogenic, vasculogenic, psychogenic, or mixed etiology. Manufactured by Pfizer (originally Pharmacia & Upjohn).
• Edex (alprostadil alfadex for injection): Approved for erectile dysfunction. Alpha-cyclodextrin complex formulation. Manufactured by Endo Pharmaceuticals.
• MUSE (alprostadil urethral suppository): Approved 1997 for erectile dysfunction. Manufactured by Meda Pharmaceuticals (now Viatris/Mylan).
• Prostin VR Pediatric (alprostadil injection, 500 mcg/mL): Approved 1981 for temporary maintenance of the patency of the ductus arteriosus in neonates with ductal-dependent congenital heart defects. Manufactured by Pfizer (originally Upjohn).

All formulations require a physician prescription. Caverject and Edex are dispensed from specialty pharmacies, and the initial dose must be administered under physician supervision.

United Kingdom (MHRA)#

Alprostadil is a licensed prescription-only medicine (POM) in the United Kingdom. Caverject and Viridal (alprostadil powder for injection) are available. The medication is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and is included in the British National Formulary (BNF) with detailed prescribing guidance.

Australia (TGA)#

Alprostadil is approved by the Therapeutic Goods Administration (TGA) as a Schedule 4 (Prescription Only Medicine). Caverject and Prostin VR are available. All dispensing requires a valid prescription.

Canada (Health Canada)#

Alprostadil is approved by Health Canada for both erectile dysfunction (Caverject) and neonatal PDA maintenance (Prostin VR Pediatric). It is a prescription drug regulated under the Food and Drugs Act.

European Union#

Alprostadil is approved in multiple EU member states through national marketing authorizations (not centralized EMA approval). Available formulations include Caverject, Edex, Viridal, and in some countries, Vitaros (topical alprostadil cream for ED, 300 mcg/dose). All formulations require a physician prescription.

Japan#

Alprostadil is approved in Japan for peripheral vascular disease (including critical limb ischemia) and has been more extensively used for vascular indications than in the United States. The lipo-PGE1 formulation (lipid microsphere-incorporated alprostadil) is widely used for chronic arterial occlusion.

At-Risk Populations#

Patients with Hematological Disorders#

Patients with sickle cell disease, sickle cell trait, thalassemia major, leukemia, multiple myeloma, polycythemia vera, and thrombocythemia are at substantially increased risk of priapism and must not use alprostadil for erectile dysfunction. These conditions affect blood rheology, coagulation, or corporal tissue integrity in ways that predispose to prolonged erections that are resistant to standard pharmacological detumescence.

Patients on Anticoagulant or Antiplatelet Therapy#

Alprostadil inhibits platelet aggregation through its EP receptor-mediated cAMP elevation in platelets. Patients receiving concurrent anticoagulation (warfarin, heparin, direct oral anticoagulants) or antiplatelet therapy (aspirin, clopidogrel) may have increased bleeding risk, particularly at injection sites (intracavernosal) or with IV administration. This is especially relevant in the neonatal PDA population, where heparin for vascular access patency is commonly coadministered.

Alprostadil use for ED is not absolutely contraindicated in patients on anticoagulants, but extra caution with injection technique (fine-gauge needle, adequate post-injection compression) and monitoring for injection-site hematoma is recommended.

Elderly Patients with Cardiovascular Disease#

Elderly patients with coronary artery disease, congestive heart failure, or cerebrovascular disease may be at increased risk from the hypotensive effects of alprostadil. While the systemic absorption from intracavernosal injection is minimal, it is not negligible, and orthostatic hypotension has been reported. Patients should be counseled about position changes and the potential for dizziness. The sexual activity itself may pose cardiovascular risk in these patients, and overall cardiovascular fitness for sexual activity should be assessed per standard guidelines (e.g., Princeton Consensus Guidelines).

Pregnant Women and Women of Childbearing Potential#

Alprostadil for ED is indicated exclusively for male patients. However, female partners may be exposed to alprostadil through vaginal absorption during intercourse. The MUSE prescribing information specifically recommends:

• Use of a condom if the female partner is or may become pregnant
• Couples seeking to conceive should not use MUSE due to potential effects on cervical anatomy
• There are no adequate studies of vaginal alprostadil exposure effects on human fertility or pregnancy

In the neonatal PDA context, alprostadil is administered to neonates of both sexes, and no sex-specific risk differences have been identified.

Premature Neonates#

Neonates with birth weight less than 2 kg and those born before 32 weeks gestational age have a higher incidence of apnea with IV alprostadil, reflecting their immature respiratory control mechanisms. These patients require:

• Lower starting doses (0.01-0.05 mcg/kg/min)
• More intensive respiratory monitoring
• Lower threshold for elective intubation before starting PGE1 infusion
• Rapid transition to definitive surgical management when feasible

Risk Mitigation#

For Clinicians Prescribing for ED#

1. Perform thorough medical history screening for priapism risk factors before prescribing
2. Conduct in-office dose titration with the patient monitored for at least 60 minutes
3. Provide hands-on injection training and technique demonstration
4. Supply written and verbal instructions about priapism recognition and emergency management
5. Schedule follow-up appointments at 1 month, 3 months, and every 6 months thereafter
6. Examine the penis for fibrosis at each follow-up visit
7. Consider transitioning to alternative treatments (PDE5 inhibitors, penile prosthesis) if complications develop

For Patients Using Alprostadil for ED#

1. Never exceed the dose prescribed by your physician
2. Do not inject more than 3 times per week, with at least 24 hours between injections
3. Rotate injection sites and use proper technique as trained
4. Seek immediate emergency medical attention if erection lasts more than 4 hours
5. Report any new lumps, nodules, or curvature of the penis to your physician promptly
6. Do not combine with other ED medications unless specifically instructed by your physician
7. Store medications according to product labeling (temperature, light protection)

For Neonatal Teams#

1. Administer only in NICU settings with continuous cardiorespiratory monitoring
2. Have intubation equipment and trained personnel immediately available
3. Start at the lowest recommended dose (0.05 mcg/kg/min) and titrate downward once ductal patency is confirmed
4. Monitor for apnea, hypotension, and temperature instability throughout the infusion
5. Plan for earliest feasible surgical correction to minimize the duration of PGE1 infusion
6. If prolonged infusion (more than 5 days) is anticipated, monitor for cortical hyperostosis and gastric outlet obstruction
7. Use precise volumetric infusion pumps; never administer as bolus injection

Comparison of Risk Profile to Investigational Compounds#

Alprostadil's risk profile is exceptionally well-characterized compared to investigational peptide compounds. Key distinctions include:

• Regulatory oversight: Full FDA review with complete toxicology, pharmacology, and clinical data packages
• Manufacturing standards: Produced under cGMP conditions with validated quality control
• Prescribing information: Comprehensive FDA-approved labeling with detailed adverse event rates, contraindications, and drug interaction data
• Pharmacovigilance: Decades of post-marketing adverse event reporting through FDA MedWatch
• Clinical experience: Millions of patient-exposures across all approved formulations
• Antidote/management protocols: Well-established emergency management protocols for the most serious adverse event (priapism)

This extensive safety characterization provides a fundamentally different risk-benefit framework compared to compounds sold as research chemicals without regulatory review, quality assurance, or established safety profiles.

Related Reading#

• Alprostadil overview and research guide
• Alprostadil side effects profile
• Alprostadil research evidence